Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.61 |
| ▸ | MMP9 | P14780 | 16/20 | 0.61 |
| ▸ | MMP1 | P03956 | 10/20 | 0.61 |
| ▸ | MMP14 | P50281 | 10/20 | 0.61 |
| ▸ | MMP13 | P45452 | 10/20 | 0.61 |
| ▸ | MMP3 | P08254 | 8/20 | 0.61 |
| ▸ | MMP8 | P22894 | 7/20 | 0.61 |
| ▸ | MMP16 | P51512 | 5/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.61 |
| ▸ | MMP12 | P39900 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404336 | 0.87 | ADAMTS4 (0.65) | MMP2MMP9MMP1MMP14MMP13 | |
| SCHEMBL20214127 | 0.76 | MMP2 (1.00) | MMP2MMP9MMP1MMP14MMP13 | |
| SCHEMBL12605175 | 0.76 | MMP2 (1.00) | MMP2MMP9MMP1MMP14MMP13 | |
| SCHEMBL13738485 | 0.76 | MMP2 (1.00) | MMP2MMP9MMP1MMP14MMP13 | |
| SCHEMBL9925900 | 0.73 | MMP2 (0.45) | MMP2MMP9MMP1MMP14MMP13 | |
| SCHEMBL403544 | 0.73 | MMP2 (0.45) | MMP2MMP9MMP1MMP14MMP13 | |
| SCHEMBL405125 | 0.73 | MMP9 (0.66) | MMP2MMP9MMP1MMP14MMP13 | |
| SCHEMBL4915104 | 0.73 | MMP9 (0.66) | MMP2MMP9MMP1MMP14MMP13 | |
| SCHEMBL5692574 | 0.71 | ADAMTS4 (0.75) | MMP2MMP9MMP1MMP14MMP13 | |
| SCHEMBL4237857 | 0.70 | MMP2 (0.51) | MMP2MMP9MMP1MMP14MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | MMP2 450/4885MMP9 1472/4885MMP1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.